ESWI webinar series 2021
How can countries cope with more than one major respiratory virus spreading, while non- pharmaceutical interventions are being loosened week by week?
What about:
- The possible co-circulation of influenza viruses, SARS-CoV-2, and RSV?
- Who belongs to high risk groups?
- Who to vaccinate and against what?
- Guidelines and regulations for co-vaccination?
- Forecasts on vaccine development?
- The use of anti-virals and antibodies during different stages of the respective infections?
Each of these challenges have been addressed in our 2021 ESWI Webinar Series.
ESWI Webinar series is supported* by
Image
![Roche](/sites/default/files/styles/large/public/2022-08/sponsor-roche.jpeg?itok=v_c-4tGA)
Image
![Janssen](/sites/default/files/styles/large/public/2022-08/sponsor-janssen.jpeg?itok=L6qTICMV)
Image
![sonafi](/sites/default/files/styles/large/public/2022-09/sanofi.jpg?itok=ayUi3SkM)
Image
![GSK](/sites/default/files/styles/large/public/2022-08/sponsor-gsk.png?itok=ZkSXq83U)
Image
![AstraZeneca](/sites/default/files/styles/large/public/2022-08/sponsor-astra.jpeg?itok=bpvG1bSB)
Image
![Seqirus](/sites/default/files/styles/large/public/2022-08/sponsor-sequirus.png?itok=ky5dgA1q)